Five Years of Cenosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the First Two Years of the FREEDOM Extension

The 3-year FREEDOM trial assessed the efficacy and safety of 60 mg denosumab every 6 months for the treatment of postmenopausal women with osteoporosis. Participants who completed the FREEDOM trial were eligible to enter an extension to continue the evaluation of denosumab efficacy and safety for up...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Papapoulos, Socrates, Chapurlat, Roland, Libanati, Cesar, Brandi, Maria Luisa, Brown, Jacques P, Czerwiński, Edward, Krieg, Marc-Antoine, Man, Zulema, Mellström, Dan, Radominski, Sebastião C, Reginster, Jean-Yves, Resch, Heinrich, Ivorra, José A Román, Roux, Christian, Vittinghoff, Eric, Austin, Matthew, Daizadeh, Nadia, Bradley, Michelle N, Grauer, Andreas, Cummings, Steven R, Bone, Henry G
Formato: Artigo
Idioma:Inglês
Publicado em: Wiley Subscription Services, Inc., A Wiley Company 2012
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3415620/
https://ncbi.nlm.nih.gov/pubmed/22113951
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbmr.1479
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados